Cargando…

Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101

BACKGROUND: This phase II trial was designed to evaluate the efficacy and safety of S‐1 combined with weekly irinotecan as a second‐ or third‐line treatment for patients with advanced or recurrent squamous cell lung cancer. METHODS: Patients with a body surface area <1.25, 1.25–1.50, and >1.50...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawashima, Yosuke, Ishimoto, Osamu, Miyauchi, Eisaku, Sakakibara, Tomohiro, Harada, Toshiyuki, Usui, Kazuhiro, Inoue, Akira, Sugawara, Shunichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518229/ https://www.ncbi.nlm.nih.gov/pubmed/37589158 http://dx.doi.org/10.1111/1759-7714.15076

Ejemplares similares

Phase II Study of Modified Carboplatin Plus Weekly Nab‐Paclitaxel in Elderly Patients with Non‐Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301
por: Miyauchi, Eisaku, et al.
Publicado: (2017)

A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202
por: Inomata, Minehiko, et al.
Publicado: (2023)

Phase I/II study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer: NJLCG1402
por: Miyauchi, Eisaku, et al.
Publicado: (2021)

Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer
por: Kinoshita, A, et al.
Publicado: (2006)

Prospective Multicenter Study of Chemotherapy-Induced Clostridium (Clostridioides) difficile Infection in Patients With Lung Cancer: North Japan Lung Cancer Study Group Trial 1204
por: Toi, Yukihiro, et al.
Publicado: (2021)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study
por: Ueoka, H, et al.
Publicado: (1999)

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1 * 28 or * 6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
por: Fukuda, Minoru, et al.
Publicado: (2016)

Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis
por: Xu, Fei, et al.
Publicado: (2018)

Irinotecan‐induced severe hypotension in a patient with lung cancer
por: Nakano, Ryota, et al.
Publicado: (2022)

Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first‐line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Probiotic Properties and Proteomic Analysis of Pediococcus pentosaceus 1101
por: Escobar-Sánchez, Monserrat, et al.
Publicado: (2022)

Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: a phase II study of Okayama Lung Cancer Study Group
por: Ueoka, H, et al.
Publicado: (2001)

Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
por: Leung, Winnie M., et al.
Publicado: (2023)

Efficacy of paclitaxel‐carboplatin with bevacizumab as a late‐line therapy for patients with advanced nonsquamous non‐small cell lung cancer: A platinum rechallenge
por: Sugisaka, Jun, et al.
Publicado: (2023)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
por: Tanaka, Hisashi, et al.
Publicado: (2022)

Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001
por: Watanabe, Kana, et al.
Publicado: (2021)

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
por: Taniguchi, Yuri, et al.
Publicado: (2022)

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027
por: Minegishi, Yuji, et al.
Publicado: (2021)

Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer.
por: Masuda, N., et al.
Publicado: (1993)

Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update
por: Lu, Jun, et al.
Publicado: (2022)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small‐cell lung cancer patients with extensive disease: A network meta‐analyses
por: Chen, Yujie, et al.
Publicado: (2017)

Impact of previous upper gastrointestinal cancer surgery on complications after lobectomy for lung cancer
por: Yamamichi, Takashi, et al.
Publicado: (2022)

A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung
por: Tsurumi, Kyoji, et al.
Publicado: (2019)

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)
por: Fujiwara, Yutaka, et al.
Publicado: (2015)

A cytogenetic survey of 1101 australian cattle of 25 different breeds
por: Halnan, CRE
Publicado: (1976)

Phase II Evaluation of VDC‐1101 in Canine Cutaneous T‐Cell Lymphoma
por: Morges, M.A., et al.
Publicado: (2014)

1101 The Gap Widens: Invasive Pneumococcal Serotype Distribution among Adults
por: Grabenstein, John D., et al.
Publicado: (2014)

1101 Is social vulnerability associated with COVID-19 among pregnant women?
por: Goulding, Alison N., et al.
Publicado: (2021)

Randomized Phase II Study of Docetaxel plus Personalized Peptide Vaccination versus Docetaxel plus Placebo for Patients with Previously Treated Advanced Wild Type EGFR Non-Small-Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2016)

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations
por: Oizumi, Satoshi, et al.
Publicado: (2018)

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
por: Murata, Yasunori, et al.
Publicado: (2023)

HAase-sensitive dual-targeting irinotecan liposomes enhance the therapeutic efficacy of lung cancer in animals
por: Zhang, Liang, et al.
Publicado: (2018)

Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
por: Narita, Daisuke, et al.
Publicado: (2023)

Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2022)

Primary lung cancer in women after previous breast cancer
por: Nobel, Tamar B, et al.
Publicado: (2022)

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h0ijh5o3tuplmd75pg5442gb5l